Purchase of eighty-three (83) 500 ML bottles of fetal bovine serum, lot #K19150.
Ended Awarded
- Contract number
- 75N91021F00002
- Awardee
-
Research And Diagnostic Systems, Inc. UEI WAYSQU5HJYT9 Part of Bio-Techne Corporation
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $24,900
Award facts
- Contract value 100% obligated
- $24,900.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325414 Biological Product (except Diagnostic) Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 2 offers Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Minneapolis, MN 55413, USA
Award details come from SAM.gov/FPDS.
About this award
The National Cancer Institute awarded a $24.9K firm fixed-price contract to Research and Diagnostic Systems, Inc. (R&D Systems) on May 25, 2021, for the purchase of eighty-three 500 ml bottles of fetal bovine serum, Lot #K19150. This contract was executed as a call against an existing Blanket Purchase Agreement and represents a non-competitive procurement. The place of performance is Minneapolis, Minnesota, where R&D Systems maintains its headquarters as a subsidiary of Bio-Techne Corporation. Fetal bovine serum is a critical biological reagent widely used in cell culture and biomedical research applications, particularly in cancer research and immunological studies supported by the National Cancer Institute.
R&D Systems has established itself as a reliable supplier to the National Institutes of Health ecosystem through its $10M single-award BPA with the Office of Logistics and Acquisition Operations, which runs through September 30, 2025. This underlying agreement enables flexible task order fulfillment for biological materials, laboratory supplies, and blood products supporting biomedical research across multiple NIH institutes. The company's federal contracting history demonstrates consistent capability in providing specialized research reagents and materials to support investigations in cancer biology, infectious disease, and translational science. The contract was completed by its ultimate completion date of May 29, 2021.
Quick answers
Who was awarded contract 75N91021F00002?
75N91021F00002 was awarded to Research And Diagnostic Systems, Inc. by National Cancer Institute (National Institutes of Health) on May 25, 2021.
How much is contract 75N91021F00002 worth?
The government has obligated $24,900 on 75N91021F00002.
Is contract 75N91021F00002 an order under another contract?
Yes. 75N91021F00002 is a BPA call under HHSN263201600021B, a blanket purchase agreement.
Was contract 75N91021F00002 competed?
The extent of competition for 75N91021F00002 was competed under sap. The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award